ASCO 2021 | Clinical trials evaluating immune checkpoint blockade and radiotherapy in head and neck cancer
Markus Hecht
• 17 May 2021
Markus Hecht, MD, PhD, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, talks on upcoming late phase clinical trials in head and neck cancer combining immune checkpoint blockade, including KEYNOTE-412 (NCT03040999), and discusses new strategies in combination approaches for patients with head and neck cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Markus Hecht, MD, PhD, has received an advisory role, speakers’ bureau, honoraria, travel expenses, and research funding from Merck Serono, MSD and BMS, research funding from AstraZeneca and Novartis, as well as travel expenses from Teva.
